• 제목/요약/키워드: Chemotherapeutics

검색결과 56건 처리시간 0.026초

간질(肝蛭) 및 췌질(膵蛭)의 화학적(化學的) 구제제(驅除劑)에 관(關)한 연구(硏究) -Hexachlorophene, Bithionol 및 Dithiazanine iodide의 시험관내(試驗管內)에서의 간질살충효력(肝蛭殺蟲效力)에 관(關)한 비교실험(比較實驗)- (Studies on Chemotherapeutics for Fasciola hepatica and Eurytrema pancreaticum -The Vermicidal Effects of Hexachlorophene, Bithionol and Dithiazanine Iodide on Fasciola hepatica in Vitro-)

  • 이창업
    • 대한수의학회지
    • /
    • 제6권1호
    • /
    • pp.45-52
    • /
    • 1966
  • Hexachlorophene, Bithionol and Dithiazanine iodide were used to examine the vermicidal effect on Fasciola hepatica in vitro. A kymographic study was performed to investigate the motility of Fasciola hepatica under the influence of these drugs. Following conclusions were made: 1) With 10,000 : 1 solution; exhibited the vermicidal effect on Fasciola hepatica, Hexachlorophene in 5 minutes, Bithionol in 10 minutes, and Dithiazanine, iodide in 40 minutes, respectively. 2) With 100,000 : 1 solution; exhibited the vermicidal effect on Fasciola hepatica, Hexachlorophene in 20 minutes and Bithionol in 30minutes. In the case of Dithiazanine iodide the stimulation upon the fluke continued for 120 minutes. 3) With 1,000,000 : 1 solution; exhibited the vermicidal effect on Fasciola hepatica, Hexachlorophene in 50 minutes and Bithionol in 80 minutes. In the case of Dithiazanine iodide the stimulation upon the fluke continued for 120 minutes. 4) With 10,000,000 : 1 solution; the only Hexachlorophene showed the vermicidal effect on Fasciola hepatica. In the case of Bithionol and Dithiazanine iodide the slight stimulation upon the fluke continued for 120 minutes.

  • PDF

Quality of Life and Chemotherapy-related Symptoms of Turkish Cancer Children Undergoing Chemotherapy

  • Arslan, Fatma Tas;Basbakkal, Zumrut;Kantar, Mehmet
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제14권3호
    • /
    • pp.1761-1768
    • /
    • 2013
  • This cross-sectional and descriptive study was designed to determine symptoms emerging due to chemotherapy treatment and their effects on children's quality of life. The research was carried out between February 2008 and February 2009 at the pediatric oncology clinics in four hospitals, focusing on 93 patients receiving chemotherapy. A survey form, the Pediatric Quality of Life Inventory (PedsQL 4.0) and the Memorial Symptom Assessment Scale (MSAS) were used as data collection tools. Chi-square and Student t tests were performed for data analysis. Some 51.6% of the children were aged 13-15 years old, and 51.8% were boys and 50.5% were diagnosed as having solid tumors. There were significant relations between: antimetabolite chemotherapeutics and feeling irritable and worrying (p=0.001, p=0.030); vinkoalkaloid and numbness/tingling in hands/feet (p=0.043); antracyclines and lack of energy and skin changes (p=0.021, p=0.004); and corticosteroids and lack of appetite, nausea and sadness (p=0.008, p=0.009, p=0.009). Several symptoms such as feeling sad, worrying and feeling irritable caused a significant decrease in the total domain of quality of life scores (p=0.034, p=0.012, p=0.010, respectively). Chemotherapeutic drugs can cause symptoms that can seriously affect quality of life in children.

Chemotherapeutic Candidate Inducing Immunological Death of Human Tumor Cell Lines

  • Oh, Su-Jin;Ryu, Chung-Kyu;Choi, In-Hak;Baek, So-Young;Lee, Hyun-Ah
    • IMMUNE NETWORK
    • /
    • 제12권2호
    • /
    • pp.66-69
    • /
    • 2012
  • The immunological death induction by EY-6 on the human tumor cell lines was screened. Human colon carcinoma (HCT15, HCT116), gastric carcinoma (MKN74, SNU668), and myeloma (KMS20, KMS26, KMS34) cells were died by EY-6 treatment with dose-dependent manner. CRT expression, a typical marker for the immunological death, was increased on the EY-6-treated colorectal and gastric cancer cells. Interestingly, the effects on the myeloma cell lines were complicated showing cell line dependent differential modulation. Cytokine secretion from the EY-6 treated tumor cells were dose and cell-dependent. IFN-${\gamma}$ and IL-12 secretion was increased in the treated cells (200% to over 1000% of non-treated control), except HCT116, SNU668 and KMS26 cells which their secretion was declined by EY-6. Data suggest the potential of EY-6 as a new type of immuno-chemotherapeutics inducing tumor-specific cell death. Further studies are planned to confirm the efficacy of EY-6 including in vivo study.

Enhanced Anti-cancer Efficacy in MCF-7 Breast Cancer Cells by Combined Drugs of Metformin and Sodium Salicylate

  • Kim, Yun-Ji;Park, Hee-Bin;Kim, Pyung-Hwan;Park, James S.;Kim, Keun-Sik
    • 대한의생명과학회지
    • /
    • 제23권3호
    • /
    • pp.290-294
    • /
    • 2017
  • Metformin or sodium salicylate is known to induce apoptosis and G0/G1 phase arrest in a variety of cancer cells. However, the anti-cancer effects of the combined treatments for these drugs-induced apoptosis are yet unclear. Here, we found that the combined treatment of metformin and sodium salicylate increased the efficacy of chemotherapeutics against breast cancer cells. These combined drugs significantly inhibited cellular proliferation and induced apoptosis at an earlier stage in human MCF-7 breast cancer cells. Also, co-treatments of metformin and sodium salicylate induced G1 cell cycle arrest in MCF-7 cells more effectively than either agent alone. Taken together, these results demonstrate that dual metformin/sodium salicylate treatment prevents proliferation of MCF-7 cells by inducing apoptosis and G1 cell cycle arrest.

Antioxidants May Protect Cancer Cells from Apoptosis Signals and Enhance Cell Viability

  • Akan, Zafer;Garip, Ayse Inhan
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제14권8호
    • /
    • pp.4611-4614
    • /
    • 2013
  • Quercetin is one of the most abundant dietary flavonoids widely present in many fruits and vegetables. Previous in vitro studies has shown that quercetin acts as an antioxidant and anti-inflammatory agent and it has potent anticarcinogenic properties as an apoptosis inducer. In this study we examined apoptotic effects of quercetin on the K562 erythroleukemia cell line. K562 cells were induced to undergo apoptosis by hydrogen peroxide. Cell viability and apoptosis level were assessed by annexin V and PI staining methods using flow cytometry. Viability of K562 cells was increased by low dose of quercetin (5-100 ${\mu}M$) for 3 hours. High doses of quercetin proved toxic (100-500 ${\mu}M$, 24 hours) and resulted in decrease of K562 cell viability as expected (p<0.01). As to results, 100 ${\mu}M$ quercetin was defined as a protective dose. Also, K562 cell apoptosis due to hydrogen peroxide was decreased in a dose dependent manner. As indicated in previous studies, reduction of superoxides by free radical scavengers like quercetin could be beneficial for prevention of cancer but consumption of such flavonoids during cancer treatment may weaken effects of chemotherapeutics and radiotherapy. Especially cancer patients should be carefully considered for traditional phytotherapy during cancer treatment, which can lead to controversial results.

소아 농흉의 임상적 고찰 (clinical analysis of childhood empyema)

  • 김범식
    • Journal of Chest Surgery
    • /
    • 제19권3호
    • /
    • pp.385-390
    • /
    • 1986
  • Empyema is a severe infection encountered in the pediatrics. With advance of the antibiotics and chemotherapeutics, there was a marked decrease in number of empyema. Empyema complicated by staphylococcal pneumonia in infant and children has been distressing problem, and the management of this complication has been discussed repeatedly in the past. In Korea, tuberculous empyema is also troublesome. If empyema is localized within thick capsule, tube thoracostomy and closed drainage alone is unacceptable, and early open thoracotomy to eliminate the empyema has proved good result. A clinical analysis of 39 patients with thoracic empyema was done. They were managed surgical intervention at Dept. of Thoracic & Cardiovascular Surgery at Kyung-Hee University Hospital from Jan. 1974 to December, 1984. 1. Age and sex distribution, infancy 9, early childhood 11. late childhood 9, puberty 10. The male to female ratio was 21:18. 2. The highest seasonal incidence was winter [21 cases]. 3. Cardinal symptoms were cough [76%], fever and chill [66%], and dyspnea [40%]. 4. The location of the empyema was right in 27 cases [69%] and 12 cases in left side. 5. The most frequent lesion to predisposing factor was pneumonia [67%]. 6. The commonest organism was Staphylococcus aureus in 15 [38%] cases, and Mycobacterium tuberculosis in 10 cases [26%]. 7. The surgical treatment was performed in all patients. The surgical procedure was closed tube thoracostomy in 25 cases [64%], decortication in 7 cases [18%], pulmonary resection in 4 cases [10%], and decortication with curettage in 2 cases. 8. One patient died from sepsis complicated by lymphoma and in one patient bronchopleural fistula was developed postoperatively.

  • PDF

Nrf2 영구 넉다운 난소암 세포주의 Proteasome 저해 항암제 Bortezomib에 대한 감수성 증가 (Enhanced Sensitivity to Proteasome Inhibitor Bortezomib in Nrf2 Knockdown Ovarian Cancer Cells)

  • 이상환;최보현;곽미경
    • 약학회지
    • /
    • 제55권6호
    • /
    • pp.466-472
    • /
    • 2011
  • NF-E2-related factor 2 (Nrf2), a master regulator of antioxidant genes in animals, has been associated with the resistance of cancer cells to several cytotoxic chemotherapeutics. Bortezomib, a reversible inhibitor of the 26S proteasome, is a novel class anti-cancer therapeutics approved for the treatment of refractory multiple myeloma. However, the molecular mechanism of drug-resistance remains elusive. In the present study, bortezomib sensitivity has been investigated in Nrf2 knockdown ovarian cancer cells. When Nrf2 expression is stably repressed using interfering RNA expression, bortezomib-induced apoptosis and cell death were significantly enhanced compared to nonspecific RNA control cells. Knockdown cells showed elevated expression in the catalytic subunit PSMB5, PSMB6, and PSMB7 compared to the control, and failed to induce heme oxygenase-1 expression following bortezomib treatment. These indicate that differential proteasome levels and altered expression of stress-response genes could be underlying mechanisms of bortezomib sensitization in Nrf2-inhibited ovarian cancer cells.

Different isolates of Miamiensis avidus showed differences in virulence to olive flounder (Paralichthys olivaceus) and in sensitivity to chemotherapeutics

  • Wakabayashi, Chizuha;Lim, Hyunju;Shin, Min Jun;Choi, Myoung Gwang;Kim, Min Sun;Kim, Ki Hong
    • 한국어병학회지
    • /
    • 제31권1호
    • /
    • pp.15-21
    • /
    • 2018
  • Differences in in vivo virulence and in sensitivity to drugs among different isolates of Miamiensis avidus were analyzed. The isolate III showed the highest resistance against the scuticocidal activity of olive flounder (Paralichthys olivaceus) serum, and induced the highest mortalities of olive flounder fingerlings. The isolate II showed significantly higher serum resistance than the isolate I, but in vivo virulence of isolate II was not significantly different from that of isolate I. The secreted proteinases activity of isolate III was significantly higher than that of isolate I and II, and the activity was significantly reduced by the addition of E-64, a cysteine proteinases inhibitor. There were no differences among isolates in the sensitivity to doxycycline, however, there were significant differences in sensitivities to mebendazole and bithionol. These results suggest that the different characteristics of different M. avidus isolates should be taken into consideration for the development of control measures against scuticociliatosis.

Leishmania Vaccines: the Current Situation with Its Promising Aspect for the Future

  • Rasit Dinc
    • Parasites, Hosts and Diseases
    • /
    • 제60권6호
    • /
    • pp.379-391
    • /
    • 2022
  • Leishmaniasis is a serious parasitic disease caused by Leishmania spp. transmitted through sandfly bites. This disease is a major public health concern worldwide. It can occur in 3 different clinical forms: cutaneous, mucocutaneous, and visceral leishmaniasis (CL, MCL, and VL, respectively), caused by different Leishmania spp. Currently, licensed vaccines are unavailable for the treatment of human leishmaniasis. The treatment and prevention of this disease rely mainly on chemotherapeutics, which are highly toxic and have an increasing resistance problem. The development of a safe, effective, and affordable vaccine for all forms of vector-borne disease is urgently needed to block transmission of the parasite between the host and vector. Immunological mechanisms in the pathogenesis of leishmaniasis are complex. IL-12-driven Th1-type immune response plays a crucial role in host protection. The essential purpose of vaccination is to establish a protective immune response. To date, numerous vaccine studies have been conducted using live/attenuated/killed parasites, fractionated parasites, subunits, recombinant or DNA technology, delivery systems, and chimeric peptides. Most of these studies were limited to animals. In addition, standardization has not been achieved in these studies due to the differences in the virulence dynamics of the Leishmania spp. and the feasibility of the adjuvants. More studies are needed to develop a safe and effective vaccine, which is the most promising approach against Leishmania infection.

Enhancing Anti-Cancer Therapy with Selective Autophagy Inhibitors by Targeting Protective Autophagy

  • Jae-Sung Park;Min Ju Lee;Seong Bin Jo;Young Ae Joe
    • Biomolecules & Therapeutics
    • /
    • 제31권1호
    • /
    • pp.1-15
    • /
    • 2023
  • Autophagy is a process of eliminating damaged or unnecessary proteins and organelles, thereby maintaining intracellular homeostasis. Deregulation of autophagy is associated with several diseases including cancer. Contradictory dual roles of autophagy have been well established in cancer. Cytoprotective mechanism of autophagy has been extensively investigated for overcoming resistance to cancer therapies including radiotherapy, targeted therapy, immunotherapy, and chemotherapy. Selective autophagy inhibitors that directly target autophagic process have been developed for cancer treatment. Efficacies of autophagy inhibitors have been tested in various pre-clinical cancer animal models. Combination therapies of autophagy inhibitors with chemotherapeutics are being evaluated in clinal trials. In this review, we will focus on genetical and pharmacological perturbations of autophagy-related proteins in different steps of autophagic process and their therapeutic benefits. We will also summarize combination therapies of autophagy inhibitors with chemotherapies and their outcomes in pre-clinical and clinical studies. Understanding of current knowledge of development, progress, and application of cytoprotective autophagy inhibitors in combination therapies will open new possibilities for overcoming drug resistance and improving clinical outcomes.